Dr. Jessie Alexander, MD
Claim this profileStudies Nail Conditions
Studies IPEX Syndrome
1 reported clinical trial
1 drug studied
Clinical Trials Jessie Alexander, MD is currently running
More about Jessie Alexander, MD
Clinical Trial Related3 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical TrialTreatments Jessie Alexander, MD has experience with
- CD4^LVFOXP3
Breakdown of trials Jessie Alexander, MD has run
Nail Conditions
IPEX Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jessie Alexander, MD specialize in?
Jessie Alexander, MD focuses on Nail Conditions and IPEX Syndrome. In particular, much of their work with Nail Conditions has involved FOXP3 positive patients, or patients who are undergoing treatment.
Is Jessie Alexander, MD currently recruiting for clinical trials?
Yes, Jessie Alexander, MD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Jessie Alexander, MD has studied deeply?
Yes, Jessie Alexander, MD has studied treatments such as CD4^LVFOXP3.
What is the best way to schedule an appointment with Jessie Alexander, MD?
Apply for one of the trials that Jessie Alexander, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.